

# Kazuki Oya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8891018/publications.pdf>

Version: 2024-02-01

22  
papers

246  
citations

1040056

9  
h-index

996975

15  
g-index

22  
all docs

22  
docs citations

22  
times ranked

505  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection—Pilot study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 400-409.	2.0	1
2	Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837.	0.7	2
3	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.1	0
4	Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 559, 78-83.	2.1	0
5	Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 267-270.	0.8	3
6	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	5.1	16
7	Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer. <i>International Cancer Conference Journal</i> , 2020, 9, 18-23.	0.5	6
8	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	2.8	10
9	Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. <i>Internal Medicine</i> , 2020, 59, 941-944.	0.7	3
10	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	7.7	27
11	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020, 50, 1234-1243.	3.4	15
12	Real-world efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 1233-1238.	0.8	3
13	Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092205.	3.2	11
14	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.8	3
15	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	2.6	14
16	<i>In vitro</i> analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. <i>Molecular Medicine Reports</i> , 2020, 23, .	2.4	5
17	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	3.3	13
18	Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2019, 97, 75-81.	1.9	44

#	ARTICLE	IF	CITATIONS
19	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.8	6
20	Levodopa Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	4.3	43
21	Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. <i>Journal of Medical Virology</i> , 2018, 90, 919-925.	5.0	8
22	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	3.4	13